Yesterday the US House of Representatives voted to pass the Senate healthcare bill in a 219-212 vote. There was also approval of a companion bill to make changes to the Senate bill. This companion bill is now going to the Senate, where action is expected later this week.
So what does the reform bill mean for the pharma industry?
One of the most important points is that drugmakers will be gaining millions of new US consumers.
The Pharmareform blog has an excellent, bullet point summary of other implications of healthcare reform on Rx drugs.
This Reuters factbox gives a rundown of "winners" and "losers" in the House healthcare bill.
You can also keep an eye on the drug stocks to see how they are affected by the reform passage:
Major Drugmaker Stock Index
Biotech Stock Index